YOLFTbeta
47

Onconic Therapeutics Inc.

476060 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

12,570.00KRW+270.00 (+2.20%)

Price History

Full chart

Market Stats

Previous Close12,300.00
Open12,370.00
Day Range12,370.00 – 13,270.00
52-Week Range8,790.00 – 28,900.00
Volume219.35K
Market Cap713.36B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg14,548.80
200-Day Avg17,900.25

About

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. John Kim Ph.D.
  • Headquarters12 Teheranro-26-gil, Seoul, South Korea, 06236, Korea
  • Websitehttps://onconic.co.kr

Leadership

  • Mr. John Kim Ph.D.Chief Executive Officer
  • Jongkil Shin M.B.A.Chief Financial Officer
  • Hyunju Cha Ph.D.Chief Scientific Officer

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue95.00M21.06B14.84B53.39B
Growth (%)-+22064.25%-29.53%+259.82%
Gross Profit95.00M21.06B14.84B53.39B
Gross Margin100.00%100.00%100.00%100.00%
Operating Expense14.93B18.83B19.64B40.77B
Operating Income-14.84B2.23B-4.80B12.62B
Operating Margin-15618.48%10.60%-32.33%23.63%
EBITDA-13.33B2.90B-8.83B14.26B
EBITDA Margin-14028.07%13.76%-59.48%26.72%
Net Income-14.43B1.68B-8.09B15.78B
Net Income Margin-15191.48%7.99%-54.54%29.56%
R&D13.18B15.76B10.93B9.72B
R&D as % of Total Revenue13877.23%74.85%73.65%18.21%
Interest Expense904.40M1.78B664.16M11.68M
Interest Expense % of Total Revenue952.00%8.43%4.48%0.02%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets30.91B37.55B60.91B75.71B
Total Liabilities52.84B57.24B4.89B3.67B
Total Equity-21.94B-19.69B56.02B72.04B
Cash27.32B30.10B43.00B47.05B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.96B4.14B-7.84B11.40B
Capital Expenditure2.58B1.16B141.28M302.90M
Free Cash Flow-17.54B2.98B-7.98B11.09B
FCF to OCF117.21%72.05%101.80%97.34%

Earnings

Report DateDec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------
EPS Actual130.2543.35-3.54212.40104.72138.9182.20
Surprise-------
Timing-------

Key Statistics & Ratios

Market Cap713.36B
Enterprise Value624.68B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.68
Price / Book8.01
Revenue (TTM)82.17B
Gross Profit (TTM)82.15B
EBITDA17.87B
Profit Margin29.51%
Operating Margin11.43%
Return on Equity33.51%
Return on Assets13.81%
Shares Outstanding45.41M
Shares Float22.95M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 10, 20254:1